Podstawowe statystyki
| CIK | 1002624 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to T. Rowe Price Health Sciences Fund Inc - T. Rowe Price Health Sciences Fund
SEC Filings (Chronological Order)
Na tej stronie znajduje się pełna, chronologiczna lista zgłoszeń SEC, z wyłączeniem zgłoszeń własności, które udostępniamy gdzie indziej.
| June 20, 2024 |
June 20, 2024 Mr. Jason Fox Division of Investment Management U.S. Securities and Exchange Commission Disclosure and Review and Accounting Office 100 F Street, N.E. Washington, D.C. 20549-4644 Re: Funds Listed in Exhibit Dear Mr. Fox: This letter responds to the Securities and Exchange Commission (SEC) Staff’s review comments discussed with Richard Sennett on June 4, 2024, related to the annual re |
|
| June 16, 2023 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 16, 2023 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2023 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| November 25, 2022 |
T. ROWE PRICE Health Sciences Fund September 30, 2022 (Unaudited) 1 Portfolio of Investments ‡ Shares $ Value (Cost and value in $000s) ‡ COMMON STOCKS 94.5% BIOTECHNOLOGY 23.2% International-Biotechnology 0.0% Ideaya Biosciences (1) 143,525 2,141 2,141 Major Biotechnology 5.6% Biogen (1) 388,006 103,598 BioNTech, ADR 938,883 126,637 Celldex Therapeutics (1) 558,393 15,696 Exact Sciences |
|
| May 27, 2022 |
T. ROWE PRICE Health Sciences Fund March 31, 2022 (Unaudited) 1 Portfolio of Investments ‡ Shares $ Value (Cost and value in $000s) ‡ COMMON STOCKS 95.2% BIOTECHNOLOGY 22.8% International-Biotechnology 0.0% Ideaya Biosciences (1) 312,628 3,498 3,498 Major Biotechnology 6.3% Alkermes (1) 74,735 1,966 Amgen 565,761 136,812 Biogen (1) 324,716 68,385 BioNTech, ADR (1) 1,158,580 197,607 Cell |
|
| November 24, 2021 |
T. ROWE PRICE Health Sciences Fund September 30, 2021 (Unaudited) 1 Portfolio of Investments ‡ Shares $ Value (Cost and value in $000s) ‡ COMMON STOCKS 96.4% BIOTECHNOLOGY 29.3% Major Biotechnology 6.3% Alkermes (1) 76,805 2,369 Amgen 634,354 134,895 Biogen (1) 526,309 148,940 BioNTech, ADR (1) 888,020 242,421 Exact Sciences (1) 1,328,703 126,825 Exact Sciences CMO Milestone, Acquisition |
|
| May 26, 2021 |
NPORT-EX 2 70F1TRPHealthSciFdInc.htm T. ROWE PRICE Health Sciences Fund March 31, 2021 (Unaudited) 1 Portfolio of Investments ‡ Shares $ Value (Cost and value in $000s) ‡ COMMON STOCKS 96.3% BIOTECHNOLOGY 29.2% Major Biotechnology 8.5% Alkermes (1) 78,048 1,458 Amgen 889,170 221,234 Biogen (1) 688,549 192,622 BioNTech, ADR (1) 1,468,694 160,367 Exact Sciences (1) 1,403,676 184,976 Exact |
|
| November 25, 2020 |
T. ROWE PRICE HEALTH SCIENCES FUND hsf70f1trowepricehealthscien.htm - Generated by SEC Publisher for SEC Filing T. ROWE PRICE HEALTH SCIENCES FUND September 30, 2020 (Unaudited) Portfolio of Investments‡ Shares/Par $ Value (Cost and value in $000s) COMMON STOCKS 97.7% BIOTECHNOLOGY 31.3% Major Biotechnology 10.5% Agenus (1) 917,037 3,668 Alkermes (1) 82,284 1,363 Amgen 1,194,964 303,712 Biogen (1) 543,953 154,309 Bristol Myers Squi |
|
| May 26, 2020 |
T. ROWE PRICE HEALTH SCIENCES FUND March 31, 2020 (Unaudited) f1trphealthsciencesfund.htm - Generated by SEC Publisher for SEC Filing T. ROWE PRICE HEALTH SCIENCES FUND March 31, 2020 (Unaudited) Portfolio of Investments‡ Shares/Par $ Value (Cost and value in $000s) COMMON STOCKS 95.0% BIOTECHNOLOGY 32.3% Major Biotechnology 13.2% Alkermes (1) 783,027 11,291 Amgen 1,416,159 287,098 Biogen (1) 728,975 230,633 Bristol-Myers Squibb 2,079,302 115,901 Exact Scien |
|
| November 25, 2019 |
PRHSX / T. Rowe Price Health Sciences Fund, Inc. NPORT-EX - - f1trphealthsciencesfund.htm - Generated by SEC Publisher for SEC Filing T. ROWE PRICE HEALTH SCIENCES FUND September 30, 2019 (Unaudited) Portfolio of Investments‡ Shares $ Value (Cost and value in $000s) COMMON STOCKS 97.8% BIOTECHNOLOGY 28.0% Major Biotechnology 9.8% Alkermes (1) 1,037,790 20,247 Amgen 1,381,700 267,373 Biogen (1) 413,924 96,370 Exact Sciences (1) 845,711 76,427 Neurocrine Biosc |
|
| May 29, 2019 |
T. Rowe Price Health Sciences Fund, Inc. NPORT-EX - - hsf70f1draft233119.htm - Generated by SEC Publisher for SEC Filing T. ROWE PRICE HEALTH SCIENCES FUND March 31, 2019 (Unaudited) Portfolio of Investments‡ Shares/Par $ Value (Cost and value in $000s) COMMON STOCKS 98.6% BIOTECHNOLOGY 30.4% Major Biotechnology 9.5% Alkermes (1) 649,326 23,694 Amgen 648,700 123,240 Array BioPharma (1) 3,354,070 81,772 Biogen (1) 330,624 78,153 Celgene (1) 1,460,700 |
|
| November 28, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 (Address of principal executive offices) David Oest |
|
| November 28, 2018 |
Item 3. CERTIFICATIONS I, David Oestreicher, certify that: |
|
| July 16, 2018 |
T. Rowe Price Dividend Growth Fund, Inc. DEF 14A IPC Email Template: USI Proxy Followup Email Subject Line: Please Vote: Upcoming Mutual Fund Shareholder Meeting and Proxy Vote We recently sent you proxy materials concerning important proposals affecting your T. |
|
| July 3, 2018 |
T. Rowe Price Balanced Fund, Inc. DEF 14A URGENT Your vote is needed today! Joint Special Meeting of T. Rowe Price Funds Dear Shareholder: The Joint Special Meeting of Shareholders to be held on July 25, 2018, at 8 a.m. ET, is quickly approaching, and our records indicate that we have not yet received your vote. Please take a few moments to vote your shares today. YOUR FUND’S BOARD RECOMMENDS THAT YOU VOTE "FOR" EACH PROPOSAL Voting now h |
|
| June 18, 2018 |
T. Rowe Price Balanced Fund, Inc. DEF 14A Dear Shareholder: Thank you for choosing electronic delivery of your T. Rowe Price Fund(s) documents. You are receiving this email because you consented to receive your proxy materials online, and we have not yet received your vote. This email provides the information you will need to view the proxy materials online, access your proxy card, and vote your shares. The Joint Special Shareholder Meeti |
|
| June 8, 2018 |
T. Rowe Price Balanced Fund, Inc. DEF 14A Vote your proxy today Vote your proxy today Dear Investor, There?s still time to vote. |
|
| May 29, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 (Address of principal executive offices) David Oest |
|
| May 29, 2018 |
Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| May 25, 2018 |
T. Rowe Price Balanced Fund, Inc. DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 10, 2018 |
T. Rowe Price Balanced Fund, Inc. DEF 14A Dear Shareholder: Thank you for choosing electronic delivery of your T. Rowe Price Fund(s) documents. You are receiving this email because you consented to receive your proxy materials online. This email provides the information you will need to view the proxy materials online, access your proxy card, and vote your shares. The Joint Special Shareholder Meeting will take place at 8:00 a.m. ET, July |
|
| April 6, 2018 |
T. Rowe Price Balanced Fund, Inc. DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 5, 2018 |
T. Rowe Price Balanced Fund, Inc. April 5, 2018 James E. O’Connor U.S. Securities and Exchange Commission Division of Investment Management 100 F Street, N.E. Washington, D.C. 20549 Re: T. Rowe Price Balanced Fund, Inc. 033-38791/811-6275 T. Rowe Price Blue Chip Growth Fund, Inc. 033-49581/811-7059 T. Rowe Price Capital Appreciation Fund, Inc. 033-05646/811-4519 T. Rowe Price Capital Appreciation & Income Fund, Inc. 333-219171/811 |
|
| March 23, 2018 |
March 23, 2018 James E. O’Connor, Esquire U.S. Securities & Exchange Commission Division of Investment Management 100 F Street, N.E. Washington, D.C. 20549 Re: T. Rowe Price Balanced Fund, Inc. 033-38791/811-6275 T. Rowe Price Blue Chip Growth Fund, Inc. 033-49581/811-7059 T. Rowe Price Capital Appreciation Fund, Inc. 033-05646/811-4519 T. Rowe Price Capital Appreciation & Income Fund, Inc. 333‐21 |
|
| March 23, 2018 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| November 28, 2017 |
T. Rowe Price Health Sciences Fund, Inc. - QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 (Address of principal executive offices) David Oest |
|
| November 28, 2017 |
Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| May 31, 2017 |
T. Rowe Price Health Sciences Fund, Inc. - QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 (Address of principal executive offices) David Oest |
|
| May 31, 2017 |
Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| February 28, 2017 |
Report of Independent Registered Public Accounting Firm EX-99.77B ACCT LTTR 2 pwchsf.htm ACCOUNT LETTER~ HEALTH SCIENCES FUND Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of T. Rowe Price Health Sciences Fund, Inc. In planning and performing our audit of the financial statements of T. Rowe Price Health Sciences Fund, Inc. ("the Company") as of and for the year ended December 31, 2016, in accordance |
|
| November 29, 2016 |
Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| November 29, 2016 |
T. Rowe Price Health Sciences Fund, Inc. - QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS nqhsf.pdf - Converted by SECPublisher 4.0, created by BCL Technologies Inc., for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 10 |
|
| October 26, 2016 |
SEC Comments and Related Responses October 25, 2016 Ms. Megan Miller Division of Investment Management U.S. Securities and Exchange Commission Office of Disclosure 100 F Street, N.E. Washington, D.C. 20549-4644 Re: Funds listed in Appendix Dear Ms. Miller: This letter responds to the Securities and Exchange Commission (?SEC?) staff?s review comments discussed with Catherine Mathews, Alan Dupski, a |
|
| May 27, 2016 |
T. Rowe Price Health Sciences Fund, Inc. - QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 (Address of principal executive offices) David Oest |
|
| May 27, 2016 |
Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| February 26, 2016 |
Report of Independent Registered Public Accounting Firm EX-99.77B ACCT LTTR 2 healthsciencesfundinc123115.htm ACCOUNT LETTER~ HEALTH SCIENCES FUND Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of T. Rowe Price Health Sciences Fund, Inc. In planning and performing our audit of the financial statements of T. Rowe Price Health Sciences Fund, Inc. ("the Company") as of and for the year ended December 31, |
|
| November 30, 2015 |
Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| November 30, 2015 |
T. Rowe Price Health Sciences Fund, Inc. - QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 (Address of principal executive offices) David Oest |
|
| May 29, 2015 |
T. Rowe Price Health Sciences Fund, Inc. - QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS N-Q 1 nqhsf.htm QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD |
|
| May 29, 2015 |
Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| February 24, 2015 |
Report of Independent Registered Public Accounting Firm healthsciencesfundinc123114.htm - Generated by SEC Publisher for SEC Filing Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of T. Rowe Price Health Sciences Fund, Inc. In planning and performing our audit of the financial statements of T. Rowe Price Health Sciences Fund, Inc. ("the Company") as of and for the year ended December 31, 2014, in accor |
|
| November 25, 2014 |
T. Rowe Price Health Sciences Fund, Inc. - QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 (Address of principal executive offices) David Oest |
|
| November 25, 2014 |
Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| May 27, 2014 |
Quarterly Schedule of Portfolio Holdings - QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 (Address of principal executive offices) David Oest |
|
| May 27, 2014 |
Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| February 26, 2014 |
T. Rowe Price Health Sciences Fund, Inc. ciphsf.htm - Generated by SEC Publisher for SEC Filing T. Rowe Price Health Sciences Fund, Inc. T. Rowe Price Health Sciences Fund The fundamental policy relating to the purchase and sale of commodities has been revised to the following: The funds may not purchase or sell commodities except to the extent permitted by applicable law. To clarify the intent of the new policy, the following note was a |
|
| February 26, 2014 |
Report of Independent Registered Public Accounting Firm healthsciencesfundinc123113.htm - Generated by SEC Publisher for SEC Filing Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of T. Rowe Price Health Sciences Fund, Inc. In planning and performing our audit of the financial statements of T. Rowe Price Health Sciences Fund, Inc. ("the Company") as of and for the year ended December 31, 2013, in accor |
|
| November 26, 2013 |
Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| November 26, 2013 |
Quarterly Schedule of Portfolio Holdings - QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 (Address of principal executive offices) David Oest |
|
| October 3, 2013 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| September 27, 2013 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| September 16, 2013 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| September 5, 2013 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 22, 2013 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 22, 2013 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 7, 2013 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 2, 2013 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| July 31, 2013 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| July 12, 2013 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 31, 2013 |
Quarterly Schedule of Portfolio Holdings - QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 (Address of principal executive offices) David Oest |
|
| May 31, 2013 |
Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| February 26, 2013 |
Report of Independent Registered Public Accounting Firm EX-99.77B ACCT LTTR 2 nsarltr-healthsciencesfundin.htm ACCOUNTING LETTER~ HEALTH SCIENCES FUND Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of T. Rowe Price Health Sciences Fund, Inc. In planning and performing our audit of the financial statements of T. Rowe Price Health Sciences Fund, Inc. ("the Company") as of and for the year ended December |
|
| November 21, 2012 |
Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| November 21, 2012 |
Quarterly Schedule of Portfolio Holdings - QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS nqhsf.pdf - Converted by SECPublisher 4.0, created by BCL Technologies Inc., for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 10 |
|
| May 30, 2012 |
Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| May 30, 2012 |
Quarterly Schedule of Portfolio Holdings - QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 (Address of principal executive offices) David Oest |
|
| February 24, 2012 |
T. Rowe Price Health Sciences Fund- Accounting Letter |
|
| November 29, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 (Address of principal executive offices) David Oest |
|
| November 29, 2011 |
Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| May 26, 2011 |
CERTIFICATIONS Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no |
|
| May 26, 2011 |
T. Rowe Price Health Sciences Fund, Inc. - March 31, 2011 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD |
|
| April 27, 2011 | ||
| February 25, 2011 | ||
| November 29, 2010 |
CERTIFICATIONS Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no |
|
| November 29, 2010 |
T. Rowe Price Health Sciences Fund, Inc. - September 30, 2010 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore |
|
| May 27, 2010 |
CERTIFICATIONS Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no |
|
| May 27, 2010 |
T. Rowe Price Health Sciences Fund, Inc. - March 31, 2010 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD |
|
| February 25, 2010 | ||
| February 25, 2010 |
EX-99.77D POLICIES 5 ciphsf.htm POLICIES~ HEALTH SCIENCES The following disclosure has been added as a type of municipal security in which the funds may invest: Build America Bonds The American Recovery and Reinvestment Act of 2009 created Build America Bonds, which allow state and local governments to issue taxable bonds in 2009 and 2010 to finance any capital expenditures for which they otherw |
|
| November 24, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 (Address of principal executive offices) David Oest |
|
| November 24, 2009 |
CERTIFICATIONS Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no |
|
| May 22, 2009 |
CERTIFICATIONS Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no |
|
| May 22, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 (Address of principal executive offices) David Oest |
|
| May 22, 2009 |
CERTIFICATIONS Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no |
|
| May 22, 2009 |
T. Rowe Price Health Sciences Fund, Inc. - March 31, 2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD |
|
| February 27, 2009 |
T. Rowe Price Health Sciences Fund, Inc. EX-99.77D POLICIES 5 ciphsf.htm POLICIES~ HEALTH SCIENCES FUND T. Rowe Price Health Sciences Fund, Inc. The fund's reserve position disclosure has been revised to state that the fund's reserve positions can also consist of U.S. dollar or non-U.S. dollar currencies. |
|
| February 27, 2009 | ||
| November 24, 2008 |
CERTIFICATIONS Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no |
|
| November 24, 2008 |
T. Rowe Price Health Sciences Fund, Inc. - September 30, 2008 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore |
|
| October 28, 2008 |
October 27, 2008 Fund Profile T. Rowe Price Industry-Focused Equity Funds A family of stock funds seeking long-term capital growth by maintaining industry-focused portfolios. This profile summarizes key information about the funds that is included in the funds` prospectus. The funds` prospectus includes additional information about the funds, including a more detailed description of the risks asso |
|
| August 26, 2008 |
T. Rowe Price Health Sciences Fund, Inc. EX-99.77D POLICIES 2 ciphsf.htm POLICIES~ HEALTH SCIENCES FUND, INC. T. Rowe Price Health Sciences Fund, Inc. The fund's reserve position disclosure has been revised to state that the fund's reserve positions can also consist of U.S. dollar or non-U.S. dollar currencies. |
|
| May 29, 2008 |
T. Rowe Price Health Sciences Fund, Inc. 3-31-08 NQ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number: 811-07381 T. Rowe Price Health Sciences Fund, Inc. (Exact name of registrant as specified in charter) 100 East Pratt Street, Baltimore, MD 21202 |
|
| May 29, 2008 |
T. Rowe Price Health Sciences Fund, Inc. - 302 Certifications Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumst |
|
| February 28, 2008 |
Report of Independent Registered Public Accounting Firm EX-99.77B ACCT LTTR 2 pwchsf.htm PWC INTERNAL CONTROL LETTER~ HEALTH SCIENCES FUND Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of T. Rowe Price Health Sciences Fund, Inc. In planning and performing our audit of the financial statements of T. Rowe Price Health Sciences Fund, Inc. ("the Company") as of and for the year ended December 31, 2007, i |
|
| November 29, 2007 |
T. Rowe Price Health Sciences Fund, Inc. - 302 Certifications Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumst |
|
| November 29, 2007 |
T. Rowe Price Health Sciences Fund, Inc. - 9/30/07 NQ ITEM 1. SCHEDULE OF INVESTMENTS T. ROWE PRICE HEALTH SCIENCES FUND Unaudited September 30, 2007 Portfolio of Investments † Shares Value (Cost and value in $000s) COMMON STOCKS 100.2% BIOTECHNOLOGY 33.6% Major Biotechnology 19.2% Alkermes (1) 1,275,000 23,460 Allos Therapeutics (1) 900,000 4,275 Amgen (1)(2) 415,000 23,477 Amicus Therapeutics (1 |
|
| May 30, 2007 |
T. Rowe Price Health Science Fund, Inc. - 302 Certifications Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumsta |
|
| May 30, 2007 |
T. Rowe Price Health Sciences Fund, Inc. - 3/31/07 NQ ITEM 1. SCHEDULE OF INVESTMENTS T. ROWE PRICE HEALTH SCIENCES FUND Unaudited March 31, 2007 Portfolio of Investments † Shares Value (Cost and value in $000s) COMMON STOCKS 101.3% BIOTECHNOLOGY 35.7% Major Biotechnology 24.8% Alkermes (1) 1,250,000 19,300 Amgen (1)(2) 677,000 37,831 Array BioPharma (1) 200,000 2,540 Biogen Idec (1) 125,000 5,547 |
|
| February 28, 2007 |
Report of Independent Registered Public Accounting Firm EX-99.77B ACCT LTTR 2 pwchsf.htm PWC INTERNAL CONTROL LETTER~HEALTH SCIENCES FUND Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of T. Rowe Price Health Sciences Fund, Inc. In planning and performing our audit of the financial statements of T. Rowe Price Health Sciences Fund, Inc. (hereafter referred to as the "Company") as of and for the year en |
|
| November 28, 2006 |
T. Rowe Price Health Sciences Fund, Inc. - 9/30/06 NQ ITEM 1. SCHEDULE OF INVESTMENTS T. ROWE PRICE HEALTH SCIENCES FUND Unaudited September 30, 2006 Portfolio of Investments † Shares Value (Cost and value in $000s) COMMON STOCKS 101.0% BIOTECHNOLOGY 40.0% Major Biotechnology 28.8% Alkermes (1) 1,175,000 18,624 Amgen (1)(2) 675,000 48,283 Array BioPharma (1) 200,000 1,704 Atherogenics (1) 150,000 |
|
| November 28, 2006 |
T. Rowe Price Health Sciences Fund, Inc. - 302 Certifications Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumst |
|
| May 25, 2006 |
I, Edward C. Bernard, certify that: 302 Certification ~ T. Rowe Price Health Sciences Fund Item 3. CERTIFICATIONS I, Edward C. Bernard, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances u |
|
| May 25, 2006 |
T. Rowe Price Health Sciences Fund ITEM 1. SCHEDULE OF INVESTMENTS T. ROWE PRICE HEALTH SCIENCES FUND Unaudited March 31, 2006 PORTFOLIO OF INVESTMENTS † Shares/$ Par Value (Cost and value in $000s) COMMON STOCKS 99.3% BIOTECHNOLOGY 43.3% Major - Biotechnology 30.9% Alkermes (1)(2) 950,000 20,947 American Pharmaceutical (2) 25,000 712 Amgen (1)(2) 675,000 49,106 Array BioPharma (2) 375,000 3,428 A |
|
| February 23, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 PAGE 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 < /p> SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Se ction 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 23, 2006 |
February 23, 2006 Keith O`Connell Securities and Exchange Commission 100 F Street, N. |
|
| February 23, 2006 |
EX-99.B1 NOTIC/SHLDR 3 finalproxy06.htm T. Rowe Price Family of Funds T. Rowe Price Funds 100 East Pratt Street Baltimore, MD 21202 Patricia B. Lippert Secretary February 28, 2006 An annual meeting of shareholders of the funds will be held on Wednesday, April 19, 2006, at 8:00 a.m., eastern time, in the offices of the funds, 100 East Pratt Street, Baltimore, MD 21202. The following matters will be |
|
| February 23, 2006 |
Report of Independent Registered Public Accounting Firm EX-99.77B ACCT LTTR 2 pwchsf.htm PWC INTERNAL CONTROL LETTER~HEALTH SCIENCES FUND Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of T. Rowe Price Health Sciences Fund, Inc. In planning and performing our audit of the financial statements of T. Rowe Price Health Sciences Fund, Inc. (hereafter referred to as the “Company”) as of and for the year en |
|
| February 23, 2006 |
FORM OF SCREEN SCRIPT FOR REGISTERED SHAREHOLDER INTERNET VOTING T. ROWE PRICE EX-99.B1 NOTIC/SHLDR 4 finalscript.htm FORM OF SCREEN SCRIPT FOR REGISTERED SHAREHOLDER INTERNET VOTING T. ROWE PRICE [Upon login to www.proxyweb.com/proxy shareholder sees Screen 1] SCREEN 1 Text 1 - (centered) Internet Proxy Voting Service Input A Please Enter Control Number from Your Proxy Card: / / / / / / Input B Check here [ ] to vote all proposals as the Board recommends, then click the VOT |
|
| February 23, 2006 |
Proxy Information This proxy material concerns the: T. Rowe Price Family of Funds Dear Shareholder: We cordially invite you to attend an annual shareholder meeting of the T. Rowe Price Funds on Wednesday, April 19, 2006. There are several items on the agenda. We ask you to read the enclosed information carefully and to submit your vote. The following matters will be considered and acted upon: All |
|
| February 23, 2006 |
EX-99.77C VOTES 5 finalproxycards06.htm [PROXY CARD #1: PROXY ITEM 1 - ELECT DIRECTORS/TRUSTEES BOARD #1 VOTE BY TOUCH-TONE PHONE, THE INTERNET, OR BY MAIL Option 1: Automated Touch Tone Voting: Call toll-free 1-888-221-0697 and follow the recorded instructions. Invest With Confidence T. Rowe Price Ram Logo Option 2: On the Internet at www.proxyweb.com and follow the on-screen instructions. Option |
|
| February 14, 2006 |
Filed on Edgar and via E-mail February 14, 2006 Keith O`Connell Securities and Exchange Commission 100 F Street, N. |
|
| February 7, 2006 |
PAGE 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 7, 2006 |
EX-99.B1 NOTIC/SHLDR 3 proxy06.htm T. Rowe Price Family of Funds T. Rowe Price Funds 100 East Pratt Street Baltimore, MD 21202 Patricia B. Lippert Secretary February 28, 2006 An annual meeting of shareholders of the funds will be held on Wednesday, April 19, 2006, at 8:00 a.m., eastern time, in the offices of the funds, 100 East Pratt Street, Baltimore, MD 21202. The following matters will be cons |
|
| February 7, 2006 |
February 7, 2006 Keith O`Connell Securities and Exchange Commission 100 F Street, N. |
|
| February 7, 2006 |
FORM OF SCREEN SCRIPT FOR REGISTERED SHAREHOLDER INTERNET VOTING T. ROWE PRICE EX-99.B1 NOTIC/SHLDR 4 script.htm FORM OF SCREEN SCRIPT FOR REGISTERED SHAREHOLDER INTERNET VOTING T. ROWE PRICE [Upon login to www.proxyweb.com/proxy shareholder sees Screen 1] SCREEN 1 Text 1 - (centered) Internet Proxy Voting Service Input A Please Enter Control Number from Your Proxy Card: / / / / / / Input B Check here [ ] to vote all proposals as the Board recommends, then click the VOTE but |
|
| February 7, 2006 |
PLEASE FOLLOW THESE INSTRUCTIONS TO VOTE BY PHONE OR INTERNET. EX-99.77C VOTES 5 allproxycards06.htm [PROXY CARD #1: PROXY ITEM 1 - ELECT DIRECTORS/TRUSTEES BOARD #1] Invest With Confidence MEETING TIME: 8:00 A.M. EASTERN TIME T. Rowe Price THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS/TRUSTEES Ram Logo Please refer to the Proxy Statement discussion of the proposal. TO VOTE BY PHONE OR INTERNET USE THE CONTROL NUMBER BELOW (SEE INSTRUCTIONS ON R |
|
| February 7, 2006 |
EX-99.B1 NOTIC/SHLDR 2 proxycoverletter.htm T. Rowe Price Annual Shareholder Meeting — T. Rowe Price Funds Proxy Cover Letter — T. Rowe Price Family of Funds T. ROWE PRICE FAMILY OF FUNDS 100 East Pratt Street Baltimore, MD 21202 P.O. Box 89000 Baltimore, MD 21289-2478 troweprice.com Proxy Information This proxy material concerns the: T. Rowe Price Family of Funds Dear Shareholder: We cordially in |
|
| November 29, 2005 |
T. Rowe Price Health Sciences Fund Item 1. Schedule of Investments T. ROWE PRICE HEALTH SCIENCES FUND Unaudited September 30, 2005 PORTFOLIO OF INVESTMENTS (1) Shares Value (Cost and value in $ 000s) COMMON STOCKS AND WARRANTS BIOTECHNOLOGY 46.4% Major Biotechnology 37.1% Abgenix * 800,000 10,144 Alkermes * 1,250,000 21,000 American Pharmaceutical * 25,000 1,142 Amgen *^ 640,000 50,989 Array BioPh |
|
| November 29, 2005 |
to state a material fact necessary to make the statements made, in light of the circumstances under - Converted by SECPublisher 3.1.0.1, created by BCL Technologies Inc., for SEC Filing Item 3. CERTIFICATIONS I, James S. Riepe, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in |
|
| May 25, 2005 |
Item 1 Schedule of Investments T. Rowe Price Health Sciences Fund (Unaudited) March 31, 2005 PORTFOLIO OF INVESTMENTS (1) Shares/$ Par Value (Cost and value in $ 000s) COMMON STOCKS AND WARRANTS BIOTECHNOLOGY 45.0% Major Biotechnology 37.4% Abgenix * 750,000 5,250 Alkermes * 1,175,000 12,196 American Pharmaceutical * 25,000 1,294 Amgen ^* 750,000 43,657 Array BioPharma * 100,000 701 Atherogenics * |
|
| May 25, 2005 |
Item 3. CERTIFICATIONS I, James S. Riepe, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| November 23, 2004 |
Item 3. CERTIFICATIONS I, James S. Riepe, certify that: 1. I have reviewed this report on Form N-Q of T. Rowe Price Health Sciences Fund, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| November 23, 2004 |
Item 1. Schedule of Investments T. Rowe Price Health Sciences Fund (Unaudited) September 30, 2004 PORTFOLIO OF INVESTMENTS (1) Shares/$ Par Value (Cost and value in $ 000s) COMMON STOCKS 99.1% BIOTECHNOLOGY 45.8% Other Biotechnology 8.8% Alexion Pharmaceutical *^ 325,000 5,850 Amylin Pharmaceuticals *^ 265,000 5,438 BioCryst Pharmaceuticals * 534,600 2,726 Cubist Pharmaceuticals * 975,000 9,633 Cy |
|
| February 25, 2002 |
NSAR-B 1 anshsf-1201.fil ANSWER FILE HSF PAGE 1 000 B000000 12/31/2001 000 C000000 0001002624 000 D000000 N 000 E000000 NF 000 F000000 Y 000 G000000 N 000 H000000 N 000 I000000 6.1 000 J000000 A 001 A000000 T. ROWE PRICE HEALTH SCIENCES FUND, INC 001 B000000 811-07381 001 C000000 4103452000 002 A000000 100 EAST PRATT STREET 002 B000000 BALTIMORE 002 C000000 MD 002 D010000 21202 003 000000 N 004 00 |
|
| September 7, 2001 |
Invest With Confidence MEETING TIME: 3:00 P.M. EASTERN TIME T. Rowe Price THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS/TRUSTEES Ram Logo Please refer to the Proxy Statement discussion of the proposal. By my signature below, I appoint the proxies indicated below to vote all Fund shares that I am entitled to vote at the Annual Meeting of Shareholders to be held on October 23, 2001, at |
|
| September 7, 2001 |
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS T. Rowe Price Funds 100 East Pratt Street Baltimore, MD 21202 Patricia B. Lippert Secretary September 7, 2001 An annual meeting of shareholders of the funds will be held on Tuesday, October 23, 2001, at 3:00 p.m., eastern time, in the offices of the funds, 100 East Pratt Street, Baltimore, MD 21202. The following matters will be acted upon at that time: 1. |
|
| September 7, 2001 |
EX-99.77C VOTES 6 pxycdscover01.txt COVER FOR PROXY CARDS PLEASE FOLLOW THESE INSTRUCTIONS TO VOTE BY PHONE OR INTERNET. (PHONE) By touch-tone telephone:(MOUSE) By computer via the internet: o have the proxy card handy o have the proxy card handy o call 1-888-221-0697 toll free o go to the Web site www.proxyweb.com o enter the control number found in the o enter the control number found in the upp |
|
| September 7, 2001 |
Proxy Information This proxy material concerns the following T. Rowe Price funds: Blue Chip Growth Portfolio Equity Income Portfolio Equity Index 500 Portfolio Health Sciences Portfolio International Stock Portfolio Limited-Term Bond Portfolio Mid-Cap Growth Portfolio New America Growth Portfolio Personal Strategy Balanced Portfolio Prime Reserve Portfolio Dear Contract Holder: We cordially invite |
|
| September 7, 2001 |
EX-99.77C VOTES 8 laportecard.txt LAPORTE PROXY CARD Invest With Confidence MEETING TIME: 3:00 P.M. EASTERN TIME T. Rowe Price THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS/TRUSTEES Ram Logo Please refer to the Proxy Statement discussion of the proposal. By my signature below, I appoint the proxies indicated below to vote all Fund shares that I am entitled to vote at the Annual Meeti |
|
| September 7, 2001 |
EX-99.77C VOTES 9 reynoldscard.txt REYNOLDS PROXY CARD Invest With Confidence MEETING TIME: 3:00 P.M. EASTERN TIME T. Rowe Price THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS/TRUSTEES Ram Logo Please refer to the Proxy Statement discussion of the proposal. By my signature below, I appoint the proxies indicated below to vote all Fund shares that I am entitled to vote at the Annual Mee |
|
| September 7, 2001 |
EX-99.77C VOTES 10 intlproxycard.txt INTERNATIONAL PROXY CARD Invest With Confidence MEETING TIME: 3:00 P.M. EASTERN TIME T. Rowe Price THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Ram Logo Please refer to the Proxy Statement discussion of the proposal. By my signature below, I appoint the proxies indicated below to vote all Fund shares that I am entitled to vote at the Annual Meeti |
|
| September 7, 2001 |
EX-99.B1 NOTIC/SHLDR 11 scriptboardonly.txt PHONE SCRIPT MANAGEMENT INFORMATION SERVICES 8/15/01 MANAGEMENT INFORMATION SERVICES PROPOSED SCRIPT FOR TELEPHONE VOTING T. ROWE PRICE FUNDS WHICH ARE VOTING FOR DIRECTORS ONLY MEETING DATE: OCTOBER 23, 2001 OPENING: When connected to the toll-free number, shareholder will hear: "Welcome. Please enter the control number located on the upper portion of y |
|
| September 7, 2001 |
EX-99.B1 NOTIC/SHLDR 3 allfdspxycover.txt COVER FOR PROXY EXCEPT FOR VAR ANN FDS Proxy Information This proxy material concerns the: T. Rowe Price Family of Funds Dear Shareholder: We cordially invite you to attend an annual shareholder meeting of the T. Rowe Price funds on Tuesday, October 23, 2001. There is only one item on the agenda, but it is an important one - the election of fund directors. |
|
| September 7, 2001 |
PAGE 1 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 25, 2000 |
PAGE 1 000 A000000 06/30/2000 000 C000000 0001002624 000 D000000 N 000 E000000 NF 000 F000000 Y 000 G000000 N 000 H000000 N 000 I000000 6. |
|
| August 25, 2000 |
6 0001002624 T. ROWE PRICE HEALTH STOCK FUND 6-MOS DEC-31-2000 JUN-30-2000 503134 664077 24869 267 0 689213 26795 0 1395 28190 0 459856 30638 18994 0 (416) 40640 0 160943 661022 1019 1051 0 2486 (416) 31062 96515 127162 0 0 0 0 18559 (6915) 0 358512 0 64427 0 0 1621 0 2496 490592 15.93 (0.01) 5.65 0 0 0 21.57 1.02 |
